Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422064 | 0.81 | ADRB1 (0.49) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL21505015 | 0.81 | ADRB1 (0.49) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL3434728 | 0.81 | ADRB1 (0.49) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL1422359 | 0.81 | ADRB1 (0.49) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL4598273 | 0.81 | IDO1 (0.47) | — | |
| SCHEMBL8490584 | 0.81 | SIGMAR1 (0.59) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL2515837 | 0.80 | TAAR1 (0.54) | HTR2ATAAR1 | |
| SCHEMBL7333026 | 0.79 | ADRB1 (0.41) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL4621588 | 0.78 | ADRB1 (0.43) | ADRB1LMNACYP2D6MEN1CYP1A2 | |
| SCHEMBL1928007 | 0.78 | TSHR (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090385-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-11 | — | — | US | disclosed |
| US-8357721-B2 | Therapy for diabetic retinopathy | MERCK PATENT GMBH (DE) | 2013-01-22 | — | — | US | disclosed |
| EP-1881960-B1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-20080182906-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| EP-1881960-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006114190-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182906-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP2 | ADRB1 3019/4885LMNA 738/4885CYP2D6 2994/4885 |
| US-20130090385-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | CASP10, CASP1, CASP2 | ADRB1 3019/4885LMNA 738/4885CYP2D6 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.